I am a board-certified medical oncologist whose practice is devoted to the care of patients with melanoma and other cancers who are receiving new immunotherapy treatments. I work closely with a multidisciplinary team of Memorial Sloan Kettering surgeons, radiation oncologists, pathologists, nurses, and patient advocates to deliver the best possible care for our patients and their families.
People with cancer have more treatment opportunities than ever before, but I believe we can do even better. My research focuses on improving immunotherapy and targeted therapy for patients with melanoma and other cancers. I am honored that my research efforts as part of a team to develop the combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) led to FDA approval in 2015 and were subsequently selected by the American Society of Clinical Oncology as a major scientific advance in melanoma care. I am grateful for opportunities to travel around the world to share the results of these advances with other medical oncologists, scientists, and patients as well as having received research awards from the Society for Immunotherapy of Cancer and the American Society of Clinical Oncology. I am also excited about having published a handbook on all aspects of oncology care, called Pocket Oncology.
I strongly believe in the importance of creating a close, trusting relationship with each patient and family as we work together for the best treatment plan possible.
- Clinical Expertise: Melanoma; Clinical Trials of New Immunotherapeutic and Targeted Therapeutic Agents
- Languages Spoken: English
- Education: MD, New York University School of Medicine
- Residencies: Brigham and Women's Hospital/Harvard Medical School
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10. PMID: 25891304
Pocket Oncology. Drilon AE, Postow MA eds. Philadelphia: Lippincott Williams & Wilkins; 2014.
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Michael A. Postow
- A Phase I Study of Ipilimumab and Nivolumab Immunotherapy plus Radiation Therapy for Metastatic Melanoma
- A Phase IB Study of IPI-549 Alone or with Nivolumab Immunotherapy in Patients with Advanced Solid Tumors
- A Phase II Study of Immunotherapy with Ipilimumab plus Nivolumab for Patients with Melanoma that Has Spread to the Brain
- A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma
Clinical Trials Co-Investigated by Michael A. Postow
- A Phase I Study of Immunotherapy with Emactuzumab and RO7009789 in Patients with Advanced Solid Tumors
- A Phase I Study of Immunotherapy with GWN323 Alone and with PDR001 in Patients with Advanced Cancers and Lymphomas
- A Phase I Study of TTI-621Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
- A Phase II Study of Immunotherapy: Ipilimumab Alone or with Nivolumab in Patients Whose Melanoma Continues to Grow Despite Nivolumab or Pembrolizumab
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more